Definitive Contract W911SR22C0051
Award Date 9/28/22
Potential Completion Date 3/31/24
Potential Value $12M
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10065, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a definitive firm fixed-price contract awarded by the Joint PEO Chemical and Biological Defense agency, a subcomponent of the U.S. Department of Defense, to Siga Technologies, Inc. The $8,999,677.03 contract is for the procurement of 23,030 oral courses and 50 intravenous courses of TPOXX, an FDA-approved therapeutic medication used for treating smallpox and related viral infections. The contract has a completion date of December 31, 2024 and does not utilize any small business set-aside...
- The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive firm fixed price contract valued at $7.4 million to Siga Technologies, Inc. of New York. The contract is to procure 10,000 courses of the FDA-approved smallpox therapeutic tecovirimat, also known as TPOXX, to replenish expiring stock within the Department of Defense stockpile. The solicitation was a sole source combined synopsis/solicitation for TPOXX as the only FDA-approved...
- <p>This is a contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Emergent Biodefense Operations Lansing LLC, also known as Emergent Biodefense, for the maintenance of a smallpox license. The contract is a delivery order with a firm fixed price of $38,430,000.00 and a completion date of January 31, 2019. The place of performance is located in Cambridge, Massachusetts. The contract does not have a set-aside designation.</p>
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a for-profit organization and subsidiary of Amerisourcebergen Corporation. The contract is for the provision of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, with a ceiling value of $1,856.75 and a performance period through April 11, 2024. This award is associated with a larger indefinite delivery contract (IDC) awarded solely to...
- This is a federal contract award to Protein Sciences Corp, a for-profit manufacturer, by the National Institute of Allergy and Infectious Diseases (NIAID) within the Department of Health and Human Services (HHS). The $33,250.00 fixed-price level of effort contract is for the procurement of TAS::75 0885::TAS IV P55, 1MG ALIQUOT, CAT # 3005, LOT # 1032-145, with a completion date of June 25, 2010. The contract is not designated as a set-aside. Protein Sciences provides specialized pandemic...
- This federal contract award is for the delivery of Oseltamivir Phosphate 75 mg capsules to the U.S. government. The contract was awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA), a combat support agency of the Department of Defense (DoD). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distribution company that provides a wide range of medical products and supplies to federal agencies, particularly the DoD and Department of Veterans...
- This is a $7,621,277 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, Massachusetts. The contract is to develop phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for treating multidrug-resistant Pseudomonas aeruginosa infections. This work was originally solicited through a Broad Agency Announcement seeking proposals to develop...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of TICOVAC 2.4 MCG/0.5 ML SYRINGE 0.5ML, a vaccine product. The contract has a ceiling value of $1,958.00 and a period of performance through May 21, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,223.51 contract is for the supply of oseltamivir phosphate 75 mg capsules, a medication used to treat and prevent influenza. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company. The $93,573.18 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication. The award falls under a larger indefinite delivery contract between Genentech and DLA valued at $27.9 million to supply medical supplies and critical pharmaceuticals for the Department of Defense. No set-aside designation was used....